A new FDA-approved combination of lurbinectedin and atezolizumab is changing the outlook for patients with extensive-stage small cell lung cancer (ES-SCLC). This first-line maintenance therapy offers a major step forward in extending survival and disease control after initial treatment.In this episode, you’ll learn: • How the lurbinectedin + atezolizumab combo improves survival and progression-free outcomes • Key findings from the IMforte Phase 3 clinical trial • What makes this treatment a new first-line maintenance option for ES-SCLC • Important safety and monitoring considerations for patients • Eligibility criteria and what it means for those in Malaysia • Why oncologists view this as a “practice-changing” advancement • How Onco Life Centre supports patients exploring new treatment optionsThis episode highlights a breakthrough that brings renewed hope to patients and families facing one of the most aggressive types of lung cancer.Blog Link: Breakthrough in Lung Cancer: Lurbinectedin Combo Offers New Hope for ES-SCLC PatientsSend us a textThank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE 📍 Visit us at oncolifecentre.com 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

Ver todos los episodios